JAC Advance Access originally published online on July 29, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 382-388
© 2003 The British Society for Antimicrobial Chemotherapy
Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS)
1 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba; Winnipeg; Departments of 2 Medicine and 3 Clinical Microbiology, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9; 4 International Health Management Associates (IHMA), Chicago, IL, USA
Received 9 December 2002; returned 25 March 2003; revised 2 April 2003; accepted 30 May 2003
Background: The purpose of this study was to assess the prevalence of vancomycin-resistant enterococci (VRE) in urinary isolates in North America, and the activity of various antibiotics against VRE.
Materials and methods: Twenty-eight medical centres in the United States and 10 centres in Canada assessed the prevalence of VRE in urinary isolates in 2002. Each study site was asked to collect up to a maximum of 50 consecutive VRE (Enterococcus faecium, Enterococcus faecalis only) urinary isolates. Susceptibility was determined by NCCLS broth microdilution. The prevalence of vanA and vanB resistance genotypes was determined by multiplex PCR.
Results: From the 28 US medical centres, a total of 697 VRE (616 [88.4%] E. faecium and 81 [11.6%] E. faecalis) were received. Approximately 75% of all VRE (E. faecium and E. faecalis) isolates demonstrated a VanA phenotype (resistance to both vancomycin and teicoplanin). PCR detection of vanA and vanB resistance determinants showed that the vanA genotype was present in 584 of 697 (83.8%) VRE isolates, whereas 113 (16.2%) isolates possessed the vanB gene. The most active agents were linezolid, nitrofurantoin and chloramphenicol, with 0.3%, 0.6% and 2.4% resistance, respectively. The majority (77.8%) of vancomycin-resistant E. faecium isolates displayed the VanA phenotype, and 538 of these 616 (87.3%) isolates were PCR-positive for vanA; the vanB genotype was detected in 78 (12.7%) isolates. Resistance was lowest with linezolid, chloramphenicol and nitrofurantoin at 0.3%, 0.3% and 0.5%, respectively. Only three genetically indistinguishable vanA-positive E. faecium were isolated from the 10 Canadian medical centres.
Conclusion: VRE urinary isolates are common in the United States, are primarily of the vanA genotype and are very susceptible to linezolid, nitrofurantoin and chloramphenicol. In Canada, VRE urinary isolates remain uncommon.
Keywords: glycopeptide resistance, urinary isolates, Enterococcus faecium
* Corresponding author. Tel: +1-204-787-4902; Fax: +1-204-787-4699; E-mail: ggzhanel{at}pcs.mb.ca
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Robinson and P. P. Nyi Probable nitrofurantoin-induced bronchiolitis obliterans with organizing pneumonia Am. J. Health Syst. Pharm., November 1, 2009; 66(21): 1919 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Zhanel, M. DeCorby, N. Laing, B. Weshnoweski, R. Vashisht, F. Tailor, K. A. Nichol, A. Wierzbowski, P. J. Baudry, J. A. Karlowsky, et al. Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006 Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1430 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Eigner, A. Fahr, M. Weizenegger, and W. Witte Evaluation of a New Molecular System for Simultaneous Identification of Four Enterococcus Species and Their Glycopeptide Resistance Genotypes J. Clin. Microbiol., June 1, 2005; 43(6): 2920 - 2922. [Abstract] [Full Text] [PDF]
|
|